Mizuho raised the firm’s price target on Apellis (APLS) to $24 from $22 and keeps a Neutral rating on the shares.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on APLS:
- Apellis Pharmaceuticals’ Promising Phase 2 Study on Geographic Atrophy Treatment
- Apellis Pharmaceuticals Launches Phase 3B Study for Pegcetacoplan in Geographic Atrophy
- Apellis Pharmaceuticals Advances APL2 Study for Rare Kidney Disease
- Apellis Pharmaceuticals Advances Pediatric PNH Treatment Study
- Apellis Pharmaceuticals’ Phase 3 Study on Pegcetacoplan: A Potential Game-Changer for Kidney Transplants